Abstract: Metabolic syndrome is a complex of abnormalities involving impaired glucose and lipid metabolism, which needs effective pharmacotherapy. One way to reduce lipid and glucose levels associated with this pathology is the simultaneous activation of nuclear PPAR-alpha and gamma. For this purpose, we synthesized a number of potential agonists based on the pharmacophore fragment of glitazars with the inclusion of mono- or diterpenic moiety in the molecular structure. The study of their pharmacological activity in mice with obesity and type 2 diabetes mellitus (C57Bl/6Ay) revealed one substance that was capable of reducing the triglyceride levels in the liver and adipose tissue of mice by enhancing their catabolism and expressing a hypoglycemic effect connected with the sensitization of mice tissue to insulin. It has also been shown to have no toxic effects on the liver.

Cite: Blokhin M.E. , Kuranov S.O. , Khvostov M.V. , Fomenko V.V. , Luzina O.A. , Zhukova N.A. , Elhajjar C. , Tolstikova T.G. , Salakhutdinov N.F.
Terpene-Containing Analogues of Glitazars as Potential Therapeutic Agents for Metabolic Syndrome
Current Issues in Molecular Biology. 2023. V.45. N3. P.2230-2247. DOI: 10.3390/cimb45030144 WOS Scopus РИНЦ

Dates:

Submitted:	Feb 1, 2023
Accepted:	Mar 2, 2023
Published print:	Mar 3, 2023
Published online:	Mar 8, 2023

Identifiers:

Web of science	WOS:000955198900001
Scopus	2-s2.0-85151118492
Elibrary	60913873
OpenAlex	W4323569649

Altmetrics: